Cambridge Cognition wins contract for a pivotal schizophrenia clinical trial

Cambridge Cognition

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it has secured a contract for a further sizeable schizophrenia trial with an existing customer.  Cambridge Cognition has been selected again to provide its proprietary gold standard digital cognitive assessments, CANTABTM, and specialist study management services.  The latest contract is worth more than £600,000 to the Company over three years.

Patients with schizophrenia often experience cognitive impairment, with deficits observed in memory, attention and executive function. CANTABTM cognitive assessments can measure these distinct processes with a high degree of sensitivity and so offers a valuable efficacy endpoint for the novel pharmaceutical being investigated.

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

“We are delighted with the enduring partnership we have formed with this client and the award of a further order for digital technology solutions from them. This is also great news for us as our strategy is to broaden our offering and expand into more therapeutic areas. Demonstrating the value of digital cognitive assessments in schizophrenia drug development could provide for many more similar opportunities in the future.”

Find more news, interviews, share price & company profile here for:
Cambridge Cognition Holdings plc

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit
Find more news, interviews, share price & company profile here for:
Cambridge Cognition Holdings plc

AIM All Share Index